



## Drug Use and Abuse in HIV

Trevor Archer\*

Department of Psychology, University of Gothenburg, Box 500, S-405 30 Gothenburg, Sweden

### Editorial

Neuropsychological testing has shown that approximately fifty percent of patients presenting HIV, in antiretroviral therapy, are afflicted by mild cognitive impairment (MCI)/HIV dementia, or other types of cognitive impairment as well as in the integrity of motor functioning, which implies that the prevalence was unaltered from the pre- to the potent antiretroviral period, although incidence of MCI had increased and HIV dementia decreased [1-3]. The presence -of neuropsychiatry co-morbidity in the pathophysiology of HIV compounds the suffering and detrimental prognosis of those afflicted with a complex relationship between HIV infection and psychiatric co-morbidity [4,5]. For example, HIV-positive status was significantly and independently associated with worse physical and mental health-related quality-of life and with an increased likelihood of depression [6]. Heroin administration, with or without smoking and cannabis, has emerged as a significantly destructive dimension of the HIV epidemic in Kenya [7]. HIV-infected smokers lose more years of life to tobacco-related disease than HIV. In cognitive testing, it has been observed that HIV-infected smokers exhibited a lower level of performance than HIV-uninfected smokers on tasks that included tests of working memory, processing speed, and intra-individual variability [8]. Furthermore, Among HIV-infected patients who smoked, neurocognitive performance was negatively associated with quality-of-life and depression ratings. A more deleterious overall symptom burden among HIV patients compared with healthy elder control subjects (n=236) with episodes of more frequent agitation, depression, anxiety, apathy, irritability and nighttime behavior disturbances has been evidenced [9]. In a large study of HIV patients, the majority of study-participants identified smoking correctly as contributing a potential cause of various smoking-related ilhealth and ill-being conditions and correctly identified constituents in cigarette smoke, although lacking knowledge concerning the effects of nicotine [10]. Taken together, the consensus emerges that individuals' self-injecting/administering drugs of abuse are confronted by barriers to their healthcare arising from reasons including co-morbidity, and particularly the case among HIV patients [11]. It should be noted that HIV-1 proteins affect novelty-seeking behavior and modulate addiction-related genes in the context of nicotine-dependent behavior [12,13].

Substance-abusing HIV individuals evidence a greater incidence of brain-related disorders [14-17]; furthermore, there is a strong relationship between drug abusers with HIV and their non-adherence to antiretroviral treatment [18,19]. Additionally, HIV-infected and HIV/hepatitis c virus-coinfected patients in opiate replacement therapy require higher methadone dose [20]. Among drug users, the analysis of HIV infection and prevention presents a relationship between drug-use and men-who-have-sex with other men, sexual behavior and sexually-transmitted diseases [21-23]. Illicit drug use among HIV-infected individuals is associated with non-adherence to HIV-medicines with the involvement of social factors modulating drug use and abuse [24-26]. In a study of 875 HIV-positive Japanese male subjects, it was found that 282 participants used addictive drugs (32.2%), with 13.8% administering illicit compounds: amphetamine/methamphetamine 5.4%, dusters/sprays/gas 3.5%, 5-methoxy-N,N-diisopropyltryptamine 1.8% and cannabis 1.0% [27], with marked links between HIV diagnosis and drug usage. In this context, the notion that

HIV-infections alters structure and functioning in brain reward systems due to infection-drug susceptibility at cellular and molecular sites [28,29], putatively accompanied by neurotoxic signaling [30]. These alterations, accordingly, appear to render the brain systems involved hypersensitive to the rewarding properties of addictive drugs [31,32]. It appears also that methamphetamine-induced CNS pathogenesis involving neurotoxicity is exacerbated in the HIV condition [33]. It has been shown also, *in vitro*, that the exposure of human and rat primary hippocampal neurons to cocaine and HIV-1 Tat reduced synergistically mitochondrial membrane potential and ATP production, as well as affecting neuronal autophagy [34]. Finally, administration of compounds with a psychostimulant action, both illicit and therapeutic drugs, increases dopamine influx into macrophages [35]. In this regard, it has been shown that the effects of dopamine, e.g. through dopamine receptor activation such as use of a psychostimulant drug, exert contribute significant influences upon the pathogenesis of HIV, and vice versa [36-38].

In conclusion, the abuse of addictive drugs disorder and the HIV-infection disease condition appear to exert a mutually, reciprocal, destructive pathophysiology that may only potentiate health loss and worsen the prognosis of those afflicted. Rehabilitation and lifestyle-adaptation must be studied more carefully if the patient situation is to be resolved.

### References

1. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. *Nat Rev Neurosci* 8: 33-44.
2. Kronemer SI, Mandel JA, Sacktor NC, Marvel CL (2017) Impairments of motor function while multitasking in HIV. *Front Hum Neurosci* 11: 212.
3. Yuan L, Wei F, Zhang X, Guo X, Lu X, et al. (2017) Intercellular adhesion molecular-5 as marker in HIV associated neurocognitive disorder. *Aging Dis* 8: 250-256.
4. Laverick R, Haddow L, Daskalopoulou M, Lampe F, Gilson R, et al. (2017) Self-reported difficulties with everyday function, cognitive symptoms and cognitive function in people with HIV. *J Acquir Immune Defic Syndr*.
5. Nedelcovych MT, Manning AA, Semenova S, Gamaldo C, Haughey NJ, et al. (2017) The psychiatric impact of HIV. *ACS Chem Neurosci*.
6. Langebeek N, Kooij KW, Wit FW, Stolte IG, Sprangers MAG, et al. (2017) Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals. *AIDS* 31: 1471-1481.
7. National AIDS Control Council of Kenya (2014) Kenya AIDS response progress report 2014, progress towards zero. Government of Kenya, Nairobi.
8. Harrison JD, Dochney JA, Blazekovic S, Leone F, Metzger D, et al. (2017) The nature and consequences of cognitive deficits among tobacco smokers with HIV: A comparison to tobacco smokers without HIV. *J Neurovirol*.

\*Corresponding author: Archer T, Department of Psychology, University of Gothenburg, Box 500, S-405 30 Gothenburg, Sweden, Tel: +46 31 7864694; E-mail: [trevor.archer@psy.gu.se](mailto:trevor.archer@psy.gu.se)

Received June 16, 2017; Accepted June 16, 2017; Published June 23, 2017

Citation: Archer T (2017) Drug Use and Abuse in HIV. *HIV Curr Res* 2: e104.

Copyright: © 2017 Archer T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9. Milanini B, Catella S, Perkovich B, Esmaeili-Firidouni P, Wendelken L, et al. (2017) Psychiatric symptom burden in older people living with HIV with and without cognitive impairment: The UCSF HIV over 60 cohort study. *AIDS Care*, pp: 1-8.
10. Pacek LR, Rass O, Johnson MW (2017) Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. *Addict Behav* 65: 81-86.
11. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I (2010) Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. *Glia* 58: 1630-9.
12. Wang L, Panagiotoglou D, Min JE, DeBeck K, Milloy MJ, et al. (2016) Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting. *Drug Alcohol Depend* 168: 22-29.
13. Yang Z, Nesil T, Connaghan KP, Li MD, Chang SL (2016) Modulation effect of HIV-1 viral proteins and nicotine on expression of the immune-related genes in brain of the HIV-1 transgenic rats. *J Neuroimmune Pharmacol* 11: 562-71.
14. Yang Z, Nesil T, Wingo T, Chang SL, Li MD (2017) HIV-1 proteins influence novelty-seeking behavior and alter region-specific transcriptional responses to chronic nicotine treatment in HIV-1Tg rats. *Nicotine Tob Res*.
15. Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, et al. (2012) Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. *Expert Opin Drug Metab Toxicol* 8: 1363-75.
16. Silverstein PS, Kumar A (2014) HIV-1 and alcohol: Interactions in the central nervous system. *Alcohol Clin Exp Res* 38: 604-10.
17. Silverstein PS, Shah A, Gupte R, Liu X, Piepho RW, et al. (2011) Methamphetamine toxicity and its implications during HIV-1 infection. *J Neurovirol* 17: 401-15.
18. Silverstein PS, Shah A, Weemhoff J, Kumar S, Singh DP, et al. (2012) HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. *Curr HIV Res* 10: 369-83.
19. Brown JL, Winhusen T, DiClemente RJ, Sales JM, Rose ES, et al. (2017) The association between cigarette smoking, virologic suppression, and CD4+ lymphocyte count in HIV-Infected Russian women. *AIDS Care*, pp: 1-5.
20. Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, et al. (2017) HIV-infected individuals who use alcohol and other drugs, and virologic suppression. *AIDS Care*, pp: 1-8.
21. Roncero C, Fuster D, Palma-Álvarez RF, Rodríguez-Cintas L, Martínez-Luna N, et al. (2017) HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study. *AIDS Care* 9: 1-6.
22. De Ryck I, Van Laeken D, Noestlinger C, Platteau T, Colebunders R (2013) The use of erection enhancing medication and party drugs among men living with HIV in Europe. *AIDS Care* 25: 1062-1066.
23. Kirby T, Thornber-Dunwell M (2013) High-risk drug practices tighten grip on London gay scene. *Lancet* 381: 101-102.
24. Li J, McDaid LM (2014) Alcohol and drug use during unprotected anal intercourse among gay and bisexual men in Scotland: what are the implications for HIV prevention? *Sex Transm Infect* 90: 125-132.
25. Daskalopoulou M, Lampe FC, Sherr L, Phillips AN, Johnson MA, et al. (2017) Non-disclosure of HIV status and associations with psychological factors, ART non-adherence, and viral load non-suppression among people living with HIV in the UK. *AIDS Behav* 21: 184-195.
26. Daskalopoulou M, Rodger A, Phillips AN, Sherr L, Speakman A, et al. (2014) Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: Results from the cross-sectional ASTRA study. *Lancet HIV* 1: e22-31.
27. Daskalopoulou M, Rodger AJ, Phillips AN, Speakman A, Lampe FC (2016) Prevalence of recreational drug use is indiscriminate across antiretroviral regimens of differing drug-drug interactions among MSM. *AIDS* 30: 810-2.
28. Togari T, Inoue Y, Takaku Y, Abe S, Hosokawa R, et al. (2016) Recreational drug use and related social factors among HIV-positive men in Japan. *AIDS Care* 28: 932-40.
29. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, et al. (2002) Molecular basis for interactions of HIV and drugs of abuse. *J Acquir Immune Defic Syndr* 31: S62-69.
30. Walter AW, Bachman SS, Reznik DA, Cabral H, Umez-Eronini A, et al. (2012) Methamphetamine use and dental problems among adults enrolled in a program to increase access to oral health services for people living with HIV/AIDS. *Public Health Rep*. 127: 25-35.
31. Hauser KF, El-Hage N, Buch S, Nath A, Tyor WR, et al. (2006) Impact of opiate-HIV-1 interactions on neurotoxic signaling. *J Neuroimmune Pharmacol* 1: 98-105.
32. Duan S, Jin Z, Liu X, Yang Y, Ye R, et al. (2017) Tobacco and alcohol use among drug users receiving methadone maintenance treatment: a cross-sectional study in a rural prefecture of Yunnan Province, Southwest China. *BMJ Open* 7: e014643.
33. Kass MD, Liu X, Vigorito M, Chang L, Chang SL (2010) Methamphetamine-induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats. *J Neuroimmune Pharmacol* 5: 566-573.
34. Castellano P, Nwagbo C, Martinez LR, Eugenin EA (2016) Methamphetamine compromises gap junctional communication in astrocytes and neurons. *J Neurochem* 137: 561-575.
35. De Simone FI, Darbinian N, Amini S, Muniswamy M, White MK, et al. (2016) HIV-1 tat and cocaine impair survival of cultured primary neuronal cells via a mitochondrial pathway. *J Neuroimmune Pharmacol* 11: 358-68.
36. Taylor SB, Lewis CR, Olive MF (2013) The neurocircuitry of illicit psychostimulant addiction: Acute and chronic effects in humans. *Subst Abuse Rehabil* 4: 29-43.
37. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, et al. (2009) Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. *Am J Pathol* 175: 1148-1159.
38. Gaskill PJ, Yano HH, Kalpana GV, Javitch JA, Berman JW (2014) Dopamine receptor activation increases HIV entry into primary human macrophages. *PLoS One* 9: e108232.

**Citation:** Archer T (2017) Drug Use and Abuse in HIV. HIV Curr Res 2: e104. HIV Curr Res 2: e014

#### OMICS International: Open Access Publication Benefits & Features

##### Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

##### Special features:

- 700+ Open Access Journals
- 50,000+ Editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: [www.omicsonline.org/submit/](http://www.omicsonline.org/submit/)